Latest Eurand Stories
Eurand has received an approvable letter from the FDA for its new drug application for EUR-1008 for the treatment of exocrine pancreatic insufficiency. The letter marks notable progress towards gaining approval and does not require Eurand to conduct additional clinical trials prior to approving EUR-1008. In addition, the FDA recently completed a successful pre-approval inspection of the company's manufacturing facilities. Eurand is working with the FDA to provide a full and timely...
- To talk saucily.
- Insolent, opprobrious language; impertinent abuse.